Evolving management of patients treated by drug-eluting stent: Prevention of late events
Summary: Drug eluting stents (DES) were introduced in clinical practice to overcome the problem of in-stent restenosis (ISR) that limited the overall efficacy of percutaneous coronary revascularization with bare metal stent (BMS). Long-term outcome data confirm a sustained benefit of DES as compared...
Hoofdauteurs: | Niccoli, G, Sgueglia, G, Montone, R, Roberto, M, Banning, A, Crea, F |
---|---|
Formaat: | Journal article |
Taal: | English |
Gepubliceerd in: |
Elsevier
2014
|
Gelijkaardige items
-
Evolving management of patients treated by drug-eluting stent: prevention of late events.
door: Niccoli, G, et al.
Gepubliceerd in: (2014) -
Which patients receiving warfarin can be treated safely with a drug-eluting stent?
door: Ryding, A, et al.
Gepubliceerd in: (2008) -
Use of a sirolimus-eluting stent to treat failure of a nonpolymer release paclitaxel-eluting stent implanted for in-stent restenosis.
door: Porto, I, et al.
Gepubliceerd in: (2005) -
Late stent thrombosis 28 months post implantation of a left main coronary drug-eluting stent.
door: Schrale, R, et al.
Gepubliceerd in: (2007) -
Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome.
door: Mack, M, et al.
Gepubliceerd in: (2011)